145 related articles for article (PubMed ID: 37003194)
1. 'I just thought that was the best thing for me to do at this point': Exploring patient experiences with depot buprenorphine and their motivations to discontinue.
Clay S; Treloar C; Degenhardt L; Grebely J; Christmass M; Gough C; Hayllar J; McDonough M; Henderson C; Crawford S; Farrell M; Marshall A
Int J Drug Policy; 2023 May; 115():104002. PubMed ID: 37003194
[TBL] [Abstract][Full Text] [Related]
2. Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study.
Johnson B; Monwell B; Capusan AJ
Harm Reduct J; 2024 Mar; 21(1):68. PubMed ID: 38528531
[TBL] [Abstract][Full Text] [Related]
3. Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia.
Barnett A; Savic M; Lintzeris N; Bathish R; Arunogiri S; Dunlop AJ; Haber P; Graham R; Hayes V; Lubman DI
Drug Alcohol Depend; 2021 Oct; 227():108959. PubMed ID: 34450472
[TBL] [Abstract][Full Text] [Related]
4. Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder.
Tompkins CNE; Neale J; Strang J
J Subst Abuse Treat; 2019 Sep; 104():64-71. PubMed ID: 31370986
[TBL] [Abstract][Full Text] [Related]
5. Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot.
Treloar C; Lancaster K; Gendera S; Rhodes T; Shahbazi J; Byrne M; Degenhardt L; Farrell M
Int J Drug Policy; 2022 Sep; 107():103788. PubMed ID: 35816790
[TBL] [Abstract][Full Text] [Related]
6. Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed-methods study.
Allen E; Samadian S; Altobelli G; Johnson J; Holmwood C
Drug Alcohol Rev; 2023 May; 42(4):791-802. PubMed ID: 36788357
[TBL] [Abstract][Full Text] [Related]
7. Prolonged-release opioid agonist therapy: qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations.
Neale J; Tompkins CNE; Strang J
Harm Reduct J; 2019 Apr; 16(1):25. PubMed ID: 30943990
[TBL] [Abstract][Full Text] [Related]
8. On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine.
Silverstein SM; Daniulaityte R; Miller SC; Martins SS; Carlson RG
Drug Alcohol Depend; 2020 May; 210():107958. PubMed ID: 32203863
[TBL] [Abstract][Full Text] [Related]
9. Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences.
Neale J; Tompkins CNE; Strang J
Drug Alcohol Rev; 2019 Jul; 38(5):510-518. PubMed ID: 31131514
[TBL] [Abstract][Full Text] [Related]
10. Non-Prescribed Substance Use during the First Month of Treatment by People Receiving Depot Buprenorphine for Opioid Use Disorder.
Parkin S; Neale J; Strang J
Subst Use Misuse; 2023; 58(13):1696-1706. PubMed ID: 37571999
[No Abstract] [Full Text] [Related]
11. Long-acting depot buprenorphine in people who are homeless: Views and experiences.
Matheson C; Foster R; Schofield J; Browne T
J Subst Abuse Treat; 2022 Aug; 139():108781. PubMed ID: 35450752
[TBL] [Abstract][Full Text] [Related]
12. Changes in Opioid Agonist Treatment Practice in Germany during the COVID-19 Pandemic: What Have Physicians Done, and What Would They Like to Keep Doing?
Lehmann K; Kuhn S; Schulte B; Verthein U
Eur Addict Res; 2023; 29(5):323-332. PubMed ID: 37557092
[TBL] [Abstract][Full Text] [Related]
13. "
Checkley L; Steiger S; Knight KR
Subst Abus; 2022; 43(1):767-773. PubMed ID: 35112998
[No Abstract] [Full Text] [Related]
14. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
[TBL] [Abstract][Full Text] [Related]
15. Patient perspectives on depot buprenorphine treatment for opioid addiction - a qualitative interview study.
Johnson B; Flensburg OL; Capusan AJ
Subst Abuse Treat Prev Policy; 2022 May; 17(1):40. PubMed ID: 35614466
[TBL] [Abstract][Full Text] [Related]
16. The dynamics of more-than-human care in depot buprenorphine treatment: A new materialist analysis of Australian patients' experiences.
Barnett A; Pienaar K; Lubman DI; Arunogiri S; Phan V; Hayes V; Lintzeris N; Savic M
Int J Drug Policy; 2024 May; 127():104399. PubMed ID: 38636315
[TBL] [Abstract][Full Text] [Related]
17. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
Geddes L; Iversen J; Wand H; Maher L
Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
[TBL] [Abstract][Full Text] [Related]
18. Patients' Perspectives on Discontinuing Buprenorphine for the Treatment of Opioid Use Disorder.
Wyse JJ; Eckhardt A; Waller D; Gordon AJ; Shull S; Lovejoy TI; Mackey K; Morasco BJ
J Addict Med; 2024 May-Jun 01; 18(3):300-305. PubMed ID: 38498620
[TBL] [Abstract][Full Text] [Related]
19. Health and correctional staff acceptability of depot buprenorphine in NSW prisons.
Little S; White B; Moensted M; Butler K; Howard M; Roberts J; Dunlop A
Int J Drug Policy; 2023 Apr; 114():103978. PubMed ID: 36870227
[TBL] [Abstract][Full Text] [Related]
20. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
[No Abstract] [Full Text] [Related]
[Next] [New Search]
